RenBio

RenBio is a preclinical biotechnology company dedicated to developing novel first-class antiviral antibody therapies and next-generation antibody delivery platforms, creating antibody-based therapeutic solutions for the treatment of cancer and inflammatory diseases. RenBio owns the proprietary MYO technology, which develops antibody therapies using DNA blueprints and an antibody factory, aiding in the treatment of rare diseases, viral infections, autoimmune diseases, and more. The company’s leading compound, RB-100, is a SARS-CoV-2 bispecific antibody licensed from Columbia University. In preclinical studies, this antibody has demonstrated potent antiviral activity against emerging and evolving SARS-CoV-2 variants. RenBio is also developing a revolutionary, next-generation nucleic acid-based antibody delivery platform—MYO (Make Your Own) Technology™—designed to overcome the manufacturing and delivery challenges of standard protein therapies. By delivering DNA "bio-blueprints" to patients (via modified intramuscular injection), muscle cells (myocytes) produce the required therapeutic antibodies within the patient's own body, thus acting as in vivo bioreactors.